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Abstract
 .  wThe restriction site mutation RSM assay see Steingrimsdottir et al. H. Steingrimsdottir, D. Beare, J. Cole, J.F.M. Leal,
T. Kostic, J. Lopez-Barea, G. Dorado, A.R. Lehmann, Development of new molecular procedures for the detection of
 . x .genetic alteration in man, Mutat. Res. 353 1996 pp. 109–121 for a review has been developed as a genotypic mutation
detection system capable of identifying mutations occurring in restriction enzyme sites of genomic DNA. Here we will
report the steps taken to overcome some of the initial problems of the assay, namely the lack of quantitative data and limited
sensitivity, the aim being to achieve a methodology suitable for the study of low dose chemical exposures. Quantitative data
was achieved in the RSM assay by the inclusion of an internal standard molecule in the PCR amplification stage, thus
allowing the calculation of both spontaneous and induced mutation frequencies. The sensitivity of the assay was increased
through the discovery that intron sequences of genomic DNA accumulated more mutations in vivo compared to the exons,
wpresumably due to differential selective pressure within genes G.J.S. Jenkins, I.deG. Mitchell, J.M. Parry, Enhanced
 .restriction site mutation RSM analysis of 1,2-dimethylhydrazine-induced mutations, using endogenous p53 intron
 . xsequences, Mutagenesis 12 1997 pp. 117–123 . This increased sensitivity was examined by applying the RSM assay to
 .analyse the persistence of N-ethyl-N-nitrosourea ENU -induced mutations in mice testes. Germ line mutations were sought
in testes DNA 3, 10 and 100 days after ENU treatment. Mutations were detected in exons and especially intron regions, the
intron mutations were more persistent, still being detected 100 days post-chemical treatment. Assignment of these mutations
as ENU induced was complicated in some cases where the spontaneous mutation level was high. This theme of mutation
 .persistence was further investigated by studying the presence of 4-nitroquinoline-1-oxide 4-NQO -induced DNA mutations
in vitro. This study also analysed the relationship between DNA adduct formation and DNA mutation induction by the
concurrent RSM analysis and 32P post-labelling analysis of 4-NQO treated human fibroblasts. The results demonstrated that
early DNA mutations detected 4 days post-treatment by the RSM assay were probably ex vivo mutations induced by Taq
polymerase misincorporation of 4-NQO adducted DNA, due to the maximum levels of 4-NQO adducts being present at this
time point. A later mutational peak, after the adduct level had declined, was assumed to be due to DNA sequence changes
produced in the fibroblasts by the in vivo processing of DNA adducts. q 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
We describe here the development of the restric-
 .tion site mutation RSM assay to the stage where it
may be employed as a sensitive mutation detection
system suitable for use at low dose exposures to
genotoxins. We also highlight some improvements
made in the assay, which clarify the relationship
between DNA sequence changes produced in experi-
mental animals and cells and those produced during
subsequent PCR amplification. These developments
were achieved through the RSM analysis of muta-
tions induced by two potent genotoxins N-ethyl-N-
 . nitrosourea ENU and 4-nitroquinoline-1-oxide 4-
.NQO .
 . w xThe restriction site mutation RSM assay 1–8 is
a genotypic mutation system capable of detecting
DNA mutations induced in restriction enzyme sites
in target DNA regions see Fig. 1 for the basic
.procedures involved in the methodology . In the
 .procedure, undigested mutated DNA is selectively
amplified by PCR, with any wild type DNA being
removed by the restriction step. The resulting en-
zyme resistant PCR product can be sequenced to
ascertain the nature of the mutation, which rendered
the enzyme site indigestible. In vivo mutational data
has been produced by the RSM assay in a variety of
w x w xstudies involving Xenopus sp. 9 , the mouse 10
w xand the rat 11 , albeit with relatively low sensitivity
 y4 y5.10 –10 and without accurate quantitative data.
 .Fig. 1. The basis of the restriction site mutation RSM assay.
Restriction enzymes fail to cut mutated recognition sites and uncut
 .mutated copies may be selectively amplified by PCR.
In order to employ the RSM assay as a research tool
in mutational studies, it is necessary for the assay to
provide sensitive quantitative data on induced muta-
genesis.
The challenge involved in developing the RSM
assay revolved around increasing the sensitivity, such
that rare mutations could be characterised and quan-
w xtified 2 . In order to provide quantitative mutational
 .data, internal standard IS molecules were synthe-
w xsised and employed in competitive PCR 12 . These
IS molecules were designed to be amplified with the
same primer pair as the target region but were
synthesised to be shorter in length by deleting the
RSM enzyme sites, thus ensuring the IS molecules
were resistant to digestion and easily identified in the
RSM analysis.The IS molecules were cloned into
plasmid vectors in order to increase their molecular
size to prevent their preferential PCR amplification.
Due to the fact that the IS molecules are included in
the PCR step of the RSM assay at a known copy
 .number approximately 50 , it was possible to quan-
titate the amplification efficiency of the PCR step.
Therefore, because the target and IS molecule share
common PCR primers it can be assumed that their
w xamplification characteristics are almost identical 13 .
Hence, it is possible to calculate the copy number of
the mutant population in the DNA before amplifica-
tion, by comparison to the post-amplification copy
number, i.e., the mutation frequency can be calcu-
lated.
In order to increase the sensitivity of the assay,
two approaches were taken. Firstly, the digestion and
amplification steps were optimised for each restric-
tion enzymerPCR primer pair, such that any muta-
tions present were readily detectable. This allowed
multiple analyses to be performed with a high proba-
bility of mutations being detected. This lead to an
y5 increase in the sensitivity from 10 single RSM
. y6 y7  .analysis to 10 –10 10–100 replicates . Sec-
ondly, several target regions of the p53 gene were
analysed by the RSM assay and it was discovered
that the non-coding intron 6 region contained ap-
proximately 10-fold more mutations than the coding
 .regions in dimethylhydrazine DMH treated mice
w x2 . This increase in mutation induction in intron 6 of
mouse p53 was also evident in two further RSM
studies involving two different genotoxic chemicals
w x  .14 . A second intron region intron 8 was also
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analysed and a similar pattern of increased intron
mutagenesis compared to the exon regions was iden-
w xtified 14 , hence the effect was not confined to a
single intron region. One explanation for our data is
that introns mutate more frequently than exons due
to the reduced selective pressure acting on non-cod-
ing regions.
The increase in RSM sensitivity, due to the target-
ing of intron regions was assessed here by evaluating
the RSM assay as a germ cell mutation detection
system. At present, there is limited information on
germ cell mutagenicity, partly due to the fact that the
current tests, such as the dominant lethal test and the
specific locus test have low sensitivity. These current
tests also fail to provide quantitative data on muta-
tion induction or any information on base specificity
of test mutagens. Germ cells are known to be less
sensitive to mutation induction than somatic cells,
this has been demonstrated by results showing that
the ENU induced adduct level in testes was 4-fold
w xlower than that of the liver 15 . The reasons for this
lower mutability include more stringent repair, higher
fidelity replication and the protective effect of the
w xSertoli cell barrier 16 . The application of the RSM
assay may provide germ line mutational data cur-
rently not available. Here, we present the results of
RSM analyses on ENU-induced mutations in the
testes of the mouse 3, 10 and 100 days post-exposure
in order to determine their persistence.
In addition to analysing the persistence of induced
mutations using the RSM assay, we also addressed
the question of the role of DNA lesions in the
detection of DNA mutations. It is possible that at
early time points post-exposure, mutational analyses
can confuse the presence of DNA lesions with DNA
mutations and these lesions could well be converted
into mutations ex vivo through Taq polymerase mis-
incorporation. This problem is also encountered in
transgenic systems, where mammalian DNA adducts
are processed in the host bacteria and ex vivo muta-
w xtions are induced 17 . This can have a profound
effect on the analyses of true DNA mutations and
ambiguous results may be produced. The analysis of
DNA lesions and their conversion to DNA mutations
ex vivo can also shed light on the process of DNA
mutagenesis, as misreplication of damaged DNA is
known to be a major source of mutations in vivo. In
order to assess the role of DNA lesions in induced
mutagenesis, human fibroblasts were treated with the
 .known genotoxin 4-nitroquinoline 1-oxide 4-NQO .
After 4-NQO treatment, the cells were cultured
through successive passages for 80 days and the
presence of DNA mutations and DNA lesions were
assessed by the concurrent application of the RSM
32 w xassay and the P post-labelling assay 18,19 .
2. Materials and methods
2.1. In ˝i˝o treatments
Male CD-1 mice Charles River UK, Manston,
. Kent were orally treated with ENU Sigma–Aldrich
.  .Poole, UK CAS No. 759-73-9 at a dose level of
275 mg kgy1 dayy1 in 1% sodium methylcarboxy-
 .cellulose SCMC . The animals were dosed on days
w x1 and 2 and groups of animals 4 were sacrificed on
w xdays 3, 10 and 100. Control animals 5 were dosed
similarly, with the vehicle only and sampled at days
3, 10 and 100. The testes were removed from the
cadavers and were homogenised in Tris–HCl pH
.7.4 before DNA extraction.
2.2. Cell lines and 4-NQO treatment
 .Human foreskin fibroblasts HF12 were cultured
in 800-ml tissue culture flasks Nunc, Roskilde, Den-
.mark using 30-ml Dulbeco’s modified Eagle medium
 .  .DMEM supplemented with 15% vrv foetal calf
 .  .serum FCS Gibco, Paisley, Scotland in a humidi-
fied atmosphere of 5% CO r95% air at 378C. The2
cells were regularly subcultured once confluence oc-
 .curred every 2–4 days . A single cell suspension
was obtained by removing the culture medium from
the confluent monolayer, washing the monolayer
twice with 20 ml of Hanks solution, then with 10 ml
of Trypsin EDTA 0.25% Trypsin, 0.02% EDTA in
.Hanks solution , after detachment had begun, the
Trypsin EDTA was removed and the flask gently
shaken. A total of 5 ml of the cell suspension was
then subcultured into 30 ml of fresh DMEMqFCS
medium in a fresh 800-ml flask and further incuba-
tion at 378C continued.
The cells were treated with 5 mM 4-NQO CAS
.No. 56-57-5 dissolved in dimethylsulphoxide
 .DMSO in 10 separate flasks, 10 flasks were also
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set up as negative controls receiving DMSO only.
The dose of 4-NQO was chosen as the concentration,
which produced 50% survival, obtained from a cyto-
 .toxicity study results not shown . After 4 h, the
media was removed, the cells washed with warm
Hanks solution and fresh media added. Two of the
10 4-NQO treatment flasks were used to extract
DNA 24 h post-treatment. The second DNA extrac-
tions occurred after 4 days using two other flasks.
The remaining six flasks were grown until conflu-
 .ency 3–4 days after 4-NQO treatment and were
subcultured into two fresh flasks each giving 12 in
.total . Two fresh flasks were sampled 24 h and 4
days after subculturing as detailed above and grown
until confluency. The process was then repeated until
 .day 80 passage number 26 . The control flasks
containing DMSO were processed similarly.
2.3. DNA extraction
2.3.1. Mouse testes samples
The DNA was extracted from the homogenised
w xtestes by the high salt method 20 using the kit of
 .the same name Stratagene, Cambridge, UK . The
concentration and purity of the DNA was analysed
by spectrophotometry at 260r280 nm. The concen-
tration was adjusted to 0.1 mgrml and the DNA was
stored at y208C.
2.3.2. Human fibroblasts
The media was removed from the cultured cells
and the monolayer was washed twice with ice cold
 .phosphate buffered saline PBS . A total of 10 ml of
ice cold PBS was added to the flasks and the cells
were scraped off the flask using a cell scraper
 ..Falcon, Oxford, UK . The cells were pelleted by
centrifugation at 2000=g for 15 min in a Beckman
J-6 centrifuge. The cell pellet was then subject to the
w xhigh salt DNA extraction method of Miller et al. 20
and its concentration and purity were checked as
above.
2.4. Construction of the internal standard for exons
4 and 5 and intron 6 of mouse p53
w xThis is detailed elsewhere 13,14 but essentially
followed the same method as for human p53 exon 7
 .below .
2.5. Construction of internal standard molecule for
human p53 exon 7
 .An IS molecule 69 bases was synthesised on a
PCR MATE DNA synthesiser ABI, Warrington,
.UK following the manufacturers recommendations.
The 69 base molecule was designed to possess the
same primer sites as the 79-bp p53 exon 7 sequence,
but had 10 bases deleted including the HaeIII and
MspI restriction sites. The 69mer was amplified by
PCR using the exon 7 specific primers and cloned
into the pCR II plasmid using the TA cloning kit
 .Invitrogen, Leck, Netherlands , in order to prevent
the preferential amplification associated with small
synthetic DNA fragments. The IS was included in
the PCR stage of the RSM assay at a copy number of
approximately 50 copies per assay. The mutation
frequency was calculated from the initial copy num-
ber of mutant genomic DNA, which was calculated
as follows:
 4nTargets N TargetrN Internal Standard
=nInternal Standard
where n denotes initial vales and N denotes final
values.
The calculated initial mutant copy number is di-
vided by the copy number of the p53 gene in 1 mg
 5.of DNA 3=10 to give the mutation frequency.
2.6. Restriction site mutation analysis
2.6.1. Mouse p53 exons 4 and 5 and intron 6
RSM analyses were performed in the two exons
w xand intron 6 as previously described 2 . Aliquots of
 .DNA 1 mg were subject to digestion with 20 units
of restriction enzyme overnight at 378C in Taq poly-
 .merase buffer Promega, Madison, WI, USA . The
restriction enzymes employed were NcoI, BanII
 .  .exon 4 ; NcoI, HaeIII, NlaIV exon 5 ; BanII and
 .HaeIII intron 6 . The digested DNA was then sub-
jected to PCR amplification. Amplification was per-
formed in a DNA engine MJ Research, Watertown,
.MA, USA with hot lid capability. The amplification
reaction contained 10 pmol of each primer, 400-mM
dNTPs, 1.5-mM MgCl , 1.25 units Taq DNA poly-2
 .merase Promega in 1= Taq polymerase buffer.
The primers, cycling conditions employed and other
w xdetails of the methodology are as Jenkins et al. 2 .
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The amplified DNA was subsequently re-restricted
with 20 units of enzyme in the manufacturer’s rec-
ommended buffer, electrophoresed on 6% polyacryl-
amide gels and stained with silver to identify any
resistant products. Resistant RSM products were iso-
lated from polyacrylamide gels using Spin-X columns
 .Costar, Cambridge, MA, USA , re-amplified by PCR
and sequenced using an ALF DNA sequencer
 .Pharmacia, Upsala, Sweden . In order to quantitate
the mutation frequencies, the resistant products were
 .applied to an ALF DNA sequencer Pharmacia and
the fluorescent intensities were compared between
the IS band and the target band.
2.6.2. Human p53 exon 7
RSM analyses were performed in the human p53
gene encompassing exon 7. PCR primers were de-
signed to amplify a 79-bp region around the hot spot
 Xcodon 248 forward primer 5 -ATGTGTAACAGT-
TCCTGCATGG-3X and reverse primer 5X-CTGAC-
X .CTGGAGTCTTCCAGTG-3 . Cycling conditions
were as follows 34 cycles of: 948C 1 min, 608C 30
.s, 728C 30 s, followed by 728C for 10 min . The
forward primer was fluoroscein labelled to allow
fluorescent intensity quantitation and the reverse
primer was biotinylated to allow immobilisation for
DNA sequencing. This hot spot region contains the
 .  .HaeIII GGCC and MspI CCGG restriction sites.
The RSM method was otherwise identical to that of
 .the mouse testes above .
2.7. 32P post-labelling method
The method employed was as described by Jones
w xet al. 21 . Calf thymus DNA was run as a negative
control and 4-NQO treated Mytilus sp. DNA was
used as a positive control. The method consisted of
hydrolysing 10 mg aliquots of DNA with micrococ-
 .cal nuclease 0.2 Urml and calf spleen phosphodi-
 .  .esterase SigmarAldrich, Poole, UK 2 mUrml for
6 h. The hydrolysed nucleotides were then enhanced
 .  .by P1 nuclease SigmarAldrich 2 mgrml diges-
w xtion to remove the normal nucleotides 22 . The
remaining nucleotides were labelled with T4 polynu-
 .cleotide kinase Boehringer-Mannheim, Lewes, UK .
The labelled nucleotides were then spotted onto TLC
 .plates BDH Merck, Poole, UK and run in four
directions with four different solutions D1: 1 M
sodium phosphate, pH 6.8; D3: 3.5 M lithium for-
mate, pH 3.5, 8.5 M urea; D4: 0.8 M lithium chlo-
ride, 0.5 M Tris–HCl, pH 8.0, 8.5 M urea; and D5:
.1.7 M sodium phosphate, pH 6.0 . The plates were
 .then exposed to hyperfilm Amersham, Bucks, UK
for 72 h. The levels of radioactive adducts were
determined using an AMBIS radioanalytical scan-
 .ning system Lablogic, Sheffield, UK . The relative
 .adduct levels RAL were calculated using the equa-
tion:
RALsAdduct cpm rtotal nucleotides cpm , .  .
cpm: counts per minute the total nucleotide cpm is
calculated from normal nucleotides without enhance-
.ment, run alongside the enhanced nucleotides .
3. Results
3.1. RSM analysis of ENU treated mouse testes
The results from the RSM analysis of ENU treated
mouse testes are shown in Table 1. These results
demonstrate that the RSM assay can detect ENU
induced and spontaneous testes mutations, even at
100 days post-treatment, the presence of spontaneous
mutations, especially in intron 6 at 100 days, leads to
a possible classification problem, these 100-day
Table 1
 .N-Ethyl-N-nitrosourea ENU induced mouse testes mutations in the p53 gene
Gene region 3 days 10 days 100 days
a a a a a aTreated Untreated Treated Untreated Treated Untreated
 .  .  .  .  .  .Exon 4 0r12 0% 0r15 0% 2r22 9% 0r17 0% 0r20 0% 0r20 0%
 .  .  .  .  .  .Exon 5 0r12 0% 0r15 0% 1r16 6% 1r16 6% 0r16 0% 0r16 0%
 .  .  .  .  .  .Intron 6 3r24 13% 0r24 0% 2r18 11% 0r16 0% 2r25 8% 2r20 10%
a  .Number of resistant RSM productsrtotal number of analyses percentage of analyses resistant .
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ENU-induced mutations may well be spontaneous in
origin. The ENU-induced mutations in exons 4 and 5
were only detectable in day 10 samples and were
undetectable after 100 days the exon 5 mutation
may also be spontaneous in origin, given the level of
.spontaneous mutations detected after 10 days . De-
spite the possible contribution of spontaneous events,
the mutations detected in the ENU treated testes can
be assumed to be predominantly due to the effect of
ENU, this is evident from the 3-fold increase in total
mutations in ENU treated testes compared to un-
 .treated testes 10:3 . The high level of spontaneous
mutations in intron 6 after 100 days compared to 3
or 10 days echoes unpublished results from our
laboratory on spontaneous bone marrow mutations,
which were also highest after 100 days. This may
reflect an increase in the spontaneous mutation rate
as these animals mature.
3.2. Mutation frequency of ENU induced testes
mutations
Table 2 shows the ENU-induced and spontaneous
mutation frequency data obtained by the inclusion of
an IS molecule in the RSM assay. The results
demonstrate a low background mutation frequency
of approximately 10y6 in the exon regions at days 3
and 100. The mutation frequency detected after 10
days in the ENU treated exon 4 region was approxi-
mately 100-fold higher than background values, but
the exon 5 values were almost identical between
ENU treated and untreated testes, perhaps reflecting
that they were both spontaneous in origin. The high-
est intron mutation frequency was obtained in the
ENU treated testes taken 100 days post-treatment.
This mutation frequency is approximately 10-fold
greater than the exon mutation frequencies and 10-
fold greater than the background mutation levels
detected, even though similar numbers of mutations
were detected between treated and untreated testes.
The spontaneous mutation frequencies detected in
intron 6 were similar to the values for the ENU
induced exon mutation frequencies, further empha-
sising the greater mutability of the intron region.
3.3. Sequence specificity of ENU induced testes
mutations
The 10 ENU-induced resistant RSM products
 .seven in intron 6, two in exon 4 and one in exon 5
yielded 14 mutations upon sequencing nine in intron
.6, three in exon 5, and two in exon 4 , with several
resistant products containing multiple mutations. The
sequencing demonstrated that the most prevalent mu-
 .tation induced was the GC“AT transition 7r14 ,
 .followed by the GC“TA transversion 4r14 , there
were also two AT“CG transition and one GC“
CG transversion. Twelve of the 14 mutations de-
tected in ENU treated testes were at GC bases with
two mutations detected at AT bases. This implicates
the O6-ethylguanine adduct as the main cause of
ENU induced testes mutation. Given that guanine is
the major target for ENU-induced mutation and given
also that, of the 14 mutations induced, 10 mutations
were at guanine bases on the non-transcribed strand,
this implicates the removal of transcribed strand
mutationsrlesions by the transcription coupled DNA
w xrepair process 23 . The three spontaneous mutations
detected contained a total of four mutational events,
three GC “ AT transitions and one GC “ TA
transversion. Fig. 2 displays the location of the ENU
induced and spontaneous mutations.
3.4. RSM analysis of 4-NQO induced DNA mutations
in human fibroblasts in ˝itro
The results of the RSM analysis of exon 7 of the
human p53 gene after 4-NQO treatment are shown
Table 2
ENU induced p53 gene mutation frequencies in mouse testes samples
Gene region 3 days 10 days 100 days
Treated Untreated Treated Untreated Treated Untreated
y6 y6 y4 y6 y6 y6Exon 4 -1.4=10 -1.4=10 1.4=10 -2.5=10 -2.3=10 -2.3=10
y6 y6 y4 y4 y6 y6Exon 5 -1.4=10 -1.4=10 1.68=10 1.6=10 -2.8=10 -2.8=10
y4 y6 y4 y6 y3 y4Intron 6 1.2=10 -0.9=10 1.7=10 -2.8=10 1.1=10 4.0=10
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Fig. 2. The location of ENU induced and spontaneous testes
mutations as detected by the RSM assay. )sSpontaneous muta-
tions.
in Table 3 and are graphically represented in Fig. 3.
The results demonstrate that two peaks of DNA
mutations appear at day 4 and day 46 post-exposure.
There were relatively few mutations detected be-
tween the two peaks and the mutations apparently
declined after 46 days, with no mutations detected in
the 64- to 80-day period. No spontaneous mutations
were detected in any control samples exposed to
DMSO alone.
3.5. Sequence specificity of 4-NQO-induced
mutations in human fibroblasts
The mutations characterised demonstrated that all
of the base substitution mutations detected by RSM
were GC“AT transitions located at the second
 .position of codon 248 CGG , as shown in Table 3.
Therefore, all mutations were detected in the MspI
site that encompassed codon 248, with no mutations
detected in the HaeIII site encompassing codon 249.
Two insertional events were detected 62 days post-
treatment. These samples contained insertions of 211
and 220 base pairs. Furthermore, given that 4NQO
targets guanine bases and that all guanine bases
targeted here were on the non-transcribed strand, this
is consistent with preferential repair of the tran-
w xscribed strand 23 .
3.6. Calculation of mutation frequency in human
fibroblasts
The mutation frequency was calculated by the
inclusion of the IS molecule in the RSM assay. The
calculated mutation frequencies are given in Table 4.
The data parallels the number of resistant RSM
 .products mutations shown in Table 3, in that there
Table 3
Number of resistant RSM products detected in exon 7 of the human p53 gene by the RSM assay after 4-NQO treatment of human
fibroblasts
aDays post-exposure Passage no. Resistant products Mutation p53 codon
1 11 3r35 GC“AT 248r2
4 11 14r32 GC“AT 248r2
10 11 6r16 GC“AT 248r2
18 12 0r12 248r2
20 13 0r20 248r2
24 14 3r18 GC“AT 248r2
31 15 2r32 GC“AT 248r2
40 16 2r46 GC“AT 248r2
44 17 10r44 GC“AT 248r2
46 18 48r56 GC“AT 248r2
50 19 7r38 GC“AT 248r2
54 20 0r41 248r2
58 21 0r49 248r2
62 22 2r48 insertions
62 22 3r48 GC“AT 248r2
64–80 23–26 0r155 248r2
a  .Number of resistant RSM productsrtotal number of analyses percentage of analyses resistants .
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Fig. 3. Graphical representation of the persistence of 4-NQO induced DNA mutations and DNA adducts. The DNA adducts are measured in
units of specific activity and these are compared with the numbers of RSM products detected.
was a high mutation frequency at days 1–10, which
drops to undetectable levels until day 24, when it
peaks again briefly, the mutation frequency then
drops until day 46 when it reaches its highest value
and then tails off becoming undetectable after 64–80
days. The spontaneous mutation frequency was esti-
mated from the number of untreated RSM analyses,
w xwhich were negative, as previously described 2 .
Table 4
32 P post-labelling and mutation frequency data for 4-NQO treated human fibroblasts
Days Passage Mutation frequency Relative adduct Specific
y6 .post-exposure number =10 level activity
1 11 21 16"2.3 51.84"7.4
4 11 15 18"5.19 58.32"16.8
10 11 15.3 11.4"5.17 36.93"16.7
18 12 ND 6.3"5.95 20"19.2
20 13 ND 1.75"1.75 0.56"0.56
24 14 14.6 ND ND
31 15 0.3 ND ND
40 16 1.27 ND ND
44 17 7.1 ND ND
46 18 510 ND ND
50 19 ND ND ND
54 20 ND ND ND
58 21 2.43 ND ND
62 22 6.5 ND ND
64–80 23–26 ND ND ND
Post-labelling negative control ND ND
Post-labelling positive control 326"36 1056"116
The spontaneous mutation frequency was estimated to be -2=10y6 for each passage.
 .ND: Not detectable .
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Given that at least 12 analyses were performed on
untreated samples at each passage, the spontaneous
mutation frequency was estimated to be -2=10y6.
3.7. 32P post-labelling of 4-NQO induced DNA
lesions in human fibroblasts
The 32 P post-labelling data is also shown in Table
4 and demonstrates high adduct levels at days 1–10,
which tail off by day 24, being undetectable there-
after. The negative control contained no detectable
adducts and the positive control 4-NQO-treated
.Mytilus sp. DNA had a value 20-fold higher than
the highest 4-NQO treated fibroblast sample. The
post-labelling results showed that the day 1, 4 and 10
samples contained two distinct adducts adjacent on
 .the TLC plates results not shown . These were
assumed to be the two 4-NQO induced adducts of
 .guanine N2-dG and C8-dG . These two adducts
were barely distinguishable and hence common
quantitative data obtained by use of the AMBIS
analyser is presented for the two adducts.
3.8. Comparison of the persistence of DNA adducts
relati˝e to DNA mutations in human fibroblasts
The comparison of the persistence of DNA adducts
and DNA mutations is displayed in Fig. 3. The
results show that the DNA adducts were detected in
days 1–18, being at a maximum at day 4. However,
their presence decreased to undetectable levels after
day 20. Fig. 3 also shows that the levels of DNA
mutations attain two peaks, at day 4 similarly to the
.DNA adducts and at day 46. A low level of DNA
mutation was detected between these two peaks and
after the second peak, no mutations were detectable
after day 62.
4. Discussion
The results presented here highlight the steps
undertaken to enhance the application of the RSM
assay. The results demonstrate the use of internal
 .standard IS molecules to produce quantitative data
on mutations induced by N-ethyl-N-nitrosourea
 .ENU in mouse testes and in human fibroblasts
 .treated with 4-nitroquinoline-1-oxide 4-NQO in
vitro. The results also demonstrate the persistence of
ENU testes mutations in vivo and 4-NQO-induced
mutations in vitro. Furthermore, by the concurrent
analysis of DNA mutations and DNA adducts in the
4-NQO treated fibroblasts, the role of DNA adducts
in mutagenesis at early time points post-treatment
could be elucidated.
The detection of germ line mutations by the RSM
assay was made possible by the demonstration that
intron regions were more sensitive to mutagenesis
w xthan exon regions 2 . The application of the RSM
assay to study germ line mutagenesis was indicative
of the increase in sensitivity achieved and represents
the first report of in vivo germ line mutations de-
tected by the RSM assay. The RSM assay has now
been developed such that it is sufficiently sensitive
to detect spontaneous germ line mutations and hence
may be employed as a germ cell mutagenicity test,
applicable to low dose exposures to genotoxins. The
RSM assay offers significant advantages over current
tests. These advantages include the quantitative anal-
ysis of any gene, the production of base specificity
information and the investigation of the role of se-
quence context.
The ENU induced mouse testes mutations were
mainly at GC bases, consistent with the formation of
O6-ethylguanine. This GC base specificity directly
contradicts reports of ENU induced transgenic muta-
tions, which were shown to be mainly at AT bases
w x16,25 . The resistant RSM products detected were
 .mainly present in the intron 6 region 7r10 , with all
the 100-day mutations being identified in this region.
This supports previous data, showing the p53 intron
6 region to be hypermutable compared to exons 4
w xand 5 2 . The third base of the BanII site in intron 6
was shown to be a hotspot for induced mutation as
w xreported previously 2 . Of the 14 mutations detected
in testes samples, six were identified at the same
 .base in the BanII site in question GGGCCC . The
next most prevalent base for mutagenesis was the
 .second base of the HaeIII site in exon 5 GGCC ,
where four of the 14 mutations were detected. All 14
mutations were detected at bases preceded by a 5XG
w xbase as predicted previously 26 . The RSM assay
was also able to detect four spontaneous germ line
w x w xmutations in exon 5 1 and intron 6 3 . The preva-
lence of intron 6 mutations is consistent with the
notion that intron mutations, being non-coding per-
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sist in the genome, whereas coding region mutations
are selected against. This was further supported by
the presence of ENU induced intron 6 mutations in
the testes, 100 days post-treatment, whereas the exon
testes mutations were only detected at day 10. The
fact that the exon mutations were only detected after
10 days, but not at 3 days supports transgenic data
showing that ENU induced testes mutations rise after
w xtreatment and reach a maximum after 35 days 15,24 .
This is a consequence of spermatogenesis where the
 .expression time 10 days involves the clonal expan-
sion of mutated spermatogonial stem cells to form
post-spermatogonial sperm cells. However, it is im-
portant to bear in mind the contribution of sponta-
neous mutations to those labelled as ENU induced,
given the high level of spontaneous mutation at
certain time points.
It is possible that the 3-day and 10-day ENU-in-
duced mouse testes mutations are the result of the
misreplication of ENU lesions ex vivo by Taq poly-
merase. However, the half life of the main mutagenic
 6 .lesion O -ethylguanine is reported to be 38 h in the
w xtestes 16 , therefore only 25% of these lesions would
be present after 3 days and less than 2% after 10
days, thus their contribution, particularly in the 10
day samples can be assumed to be minimal.
The concurrent analysis of DNA adducts and
DNA mutations in human fibroblasts treated in vitro
with 4-NQO appears to implicate DNA adducts in
producing ex vivo DNA mutations at early time
points. The adducts were shown to peak at day 4 and
decline to undetectable levels after day 20, whereas
two mutational peaks at day 4 and day 46 were
detected. The first peak of mutation induction at day
4 is probably due to the miscoding of the 4-NQO
lesions by Taq DNA polymerase in the RSM assay,
due to the fact that this corresponds to the days
where DNA adducts were at a maximum. However,
the second mutational peak, at day 46, is presumably
due to genuine fixed mutations, induced in the cells
by the in vivo miscoding of 4-NQO adducts during
cell division. Hence, it has been possible to estimate
the expression time of 4-NQO induced mutagenesis
 .in treated human fibroblasts about 20 days . This
expression time represents the time taken for all
4-NQO induced DNA adducts to be converted into
DNA mutations during successive rounds of cell
division. This information may provide a better un-
derstanding of the role of DNA adduct processing
within cells and hence could lead to better dosing
and sampling regimes in future mutation studies.
These results also indicate the potential use of the
RSM assay at early expression times to detect DNA
adducts as an alternative to the use of the post-label-
ling assay.
The subsequent reduction in DNA mutations after
46 days suggests that the human fibroblasts are
actively selecting against DNA mutations in the
hotspot regions of exon 7 of the p53 gene unlike
the intron mutations in the testes which persisted for
.100 days . This experiment is currently being ex-
tended to include both intron and exon targets in
order to determine if the selection against exon 7
mutations described in this paper is evident for the
intron regions, or whether the intron mutations, be-
ing non-coding, are tolerated.
The 4-NQO-induced mutations identified by the
RSM assay are consistent with those expected from
the published data. 4-NQO’s major DNA base target
w xhas been shown to be guanine 27 . The predominant
mutation detected was shown to be the GC“AT
w xtransition, supporting earlier data 28,29 . The se-
quence specificity of the 4-NQO-induced mutations
 .at the second base of codon 248 may reflect the
sequence context of this codon. This hotspot codon
CGG contains the highly mutable CpG dinucleotide
w x30 which has been shown to spontaneously deami-
w xnate after cytosine methylation 31 . Deamination at
the CpG dinucleotide on the transcribed strand would
yield a GC“AT transition at the second base of
codon 248. Hence, it is conceivable that increased
deamination of methyl-cytosine when it is paired
opposite 4-NQO adducted guanine could provide an
alternative mechanism to misreplication of adducted
guanine residues resulting in the sequence specific
mutations detected in this study. The deamination of
methyl-cytosine has been shown to be increased
w xwhen paired opposite alkylated guanine 32 . The
contribution of spontaneous events to the 4-NQO-in-
duced mutation detected here, is negligible, as no
mutations were detectable in the untreated cells.
The fact that all the 4-NQO induced base substitu-
tion mutations were located on the non-transcribed
strand suggests that transcription coupled DNA re-
w xpair 23 occurred, removing the DNA damage from
the transcribed strand. In a study of ENU induced
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mutagenesis in human p53 exon 7, GC“AT transi-
tions were reported at the second base of codon 248
w xon the non-transcribed strand 33 , identical to that of
4-NQO mutations detected here. Thus, a similar
mechanism involving the preferential deamination of
methyl cytosine when placed opposite adducted gua-
nine residues, may be responsible for these results
and these reports together may explain why codon
248 is frequently mutated in many human cancers.
The spectrum of 4-NQO-induced mutations in
human fibroblasts did not alter significantly with
expression time, although two complex insertional
events were induced at day 62, which were not
apparent at earlier time points. The 211-bp and
220-bp insertional events at 62 days post-exposure
represented DNA sequences, which were unidentifi-
able by comparison with the GenbankrEMBL
databases and hence their origin is unknown. These
later insertions may reflect the chronic DNA damage
induced as a result of p53 inactivation. It is known
that the p53 gene product plays a major role in
w xprotecting the genome from DNA damage 34 , hence
if the p53 gene becomes inactivated, it is possible
that gross structural changes may occur unchecked.
The p53 gene is known to be inactivated by point
mutations in codon 248 and this represents the most
frequent p53 mutation associated with human cancer
w x35 . Therefore, due to the fact that all the mutations
induced by 4-NQO were in codon 248, it is conceiv-
able that the p53 gene was inactivated in these cells
and hence they may have become genetically unsta-
ble, which would account for the insertional events
detected.
Therefore, in summary, the RSM assay has been
shown to detect 4-NQO-induced mutations in vitro
and provide information on the role of DNA adducts
and also, more significantly, it has been possible to
detect both ENU induced and spontaneous germ line
mutations. Hence the development of the RSM assay
has progressed such that it may now be applied to
detect rare DNA mutations and provide quantitative
mutational data at low dose exposures to genotoxins.
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